Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) reported on Tuesday that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination in MS patients. Preliminary imaging data from the study have shown encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions, which the company believes could significantly enhance the development of MS therapies, including its investigational candidate Lucid-MS.
The milestone comes as Quantum BioPharma continues to advance its pipeline of treatments for neurodegenerative disorders. The company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for a Phase 2 trial of Lucid-MS in March 2026. Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models, addressing the underlying mechanism of multiple sclerosis.
The imaging study is being conducted in collaboration with Massachusetts General Hospital, a leading research institution. The use of the [¹⁸F]3F4AP tracer allows for direct visualization of demyelination, which could provide a more accurate assessment of disease progression and treatment response. By reaching the midpoint enrollment target, the study is on track to generate robust data that may support the clinical development of Lucid-MS and other MS therapies.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on advancing Lucid-MS. Additionally, Quantum invented UNBUZZD(TM), a product for alcohol misuse, and spun out its over-the-counter version to Unbuzzd Wellness Inc. Quantum retains a 19.84% stake in Unbuzzd as of March 31, 2026, and receives royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. For more information on the full press release, visit https://ibn.fm/4IZ0y.
